ginisortamab

DRUG2 trials

Sponsors

Cancer Research UK, UCB Biopharma SRL

Conditions

Advanced Solid TumorsMetastatic pancreatic ductal adenocarcinoma

Phase 1

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

CompletedNCT04393298

UCB Biopharma SRLAdvanced Solid Tumors

Start: 2020-07-09End: 2024-04-11Updated: 2025-05-29

Phase 2

A Cancer Research UK Phase II open label trial in participants with metastatic pancreatic ductal adenocarcinoma of ginisortamab given intravenously I) with first-line standard of care nab-paclitaxel and gemcitabine, or II) in combination with MEK inhibitor maintenance therapy

RecruitingCTIS2024-514129-43-00

Cancer Research UKMetastatic pancreatic ductal adenocarcinoma

Start: 2025-01-15Target: 43Updated: 2025-09-15

Related Papers

A dose-finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti-gremlin-1 monoclonal antibody, in patients with solid tumours.

2026-04-30

CRUK: Phase II trial of ginisortamab with (1) 1st-line gemcitabine + nab-paclitaxel (AG) or (2) MEK inhibitor as maintenance therapy in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Journal of Clinical Oncology2026-01-10

Abstract CT156: Phase 1 dose-optimization study evaluating the safety of ginisortamab (UCB6114), an anti-gremlin-1 monoclonal antibody (mAb) with first-in-class potential, as monotherapy in advanced solid tumors

Cancer Research2025-04-25

Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer

mAbs2023-12-1212 citations

Abstract CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors

Cancer Research2023-04-145 citations

A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors.

Journal of Clinical Oncology2022-01-192 citations